Microenvironment drug resistance in multiple myeloma: emerging new players

Lucia Di Marzo; Vanessa Desantis; Antonio Giovanni Solimando; Simona Ruggieri; Tiziana Annese; Beatrice Nico; Ruggiero Fumarulo; Angelo Vacca; Maria Antonia Frassanito

doi:10.18632/oncotarget.10849

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Microenvironment drug resistance in multiple myeloma: emerging new players

Lucia Di Marzo, Vanessa Desantis, Antonio Giovanni Solimando, Simona Ruggieri, Tiziana Annese, Beatrice Nico, Ruggiero Fumarulo, Angelo Vacca _ and Maria Antonia Frassanito

PDF | HTML | How to cite

Oncotarget. 2016; 7:60698-60711. https://doi.org/10.18632/oncotarget.10849

Metrics: PDF 4985 views | HTML 6283 views | ?

Abstract

Lucia Di Marzo1,*, Vanessa Desantis1,*, Antonio Giovanni Solimando1, Simona Ruggieri2, Tiziana Annese2, Beatrice Nico2, Ruggiero Fumarulo3, Angelo Vacca1 and Maria Antonia Frassanito3

1 Department of Biomedical Sciences and Human Oncology, Internal Medicine Section, University of Bari Medical School, Bari, Italy

2 Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy

3 Department of Biomedical Sciences and Human Oncology, General Pathology Section, Bari, Italy

* These authors have contributed equally to this work

Correspondence to:

Angelo Vacca, email:

Keywords: cancer-associated fibroblasts, drug resistance, exosomes, microRNAs, multiple myeloma

Received: May 05, 2016 Accepted: July 11, 2016 Published: September 13, 2016

Abstract

Multiple myeloma (MM) drug resistance (DR) is a multistep transformation process based on a powerful interplay between bone marrow stromal cells and MM cells that allows the latter to escape anti-myeloma therapies. Here we present an overview of the role of the bone marrow microenvironment in both soluble factors-mediated drug resistance (SFM-DR) and cell adhesion-mediated drug resistance (CAM-DR), focusing on the role of new players, namely miRNAs, exosomes and cancer-associated fibroblasts.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10849

Publication Alerts

Oncoscience

Post-Publication Promotion

Reviews:

Microenvironment drug resistance in multiple myeloma: emerging new players

Abstract